Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa McWilliams

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2022
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and TrapperGiuditta Illuzzi, Anna D Staniszewska, Sonja J Gill, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|July 8, 2026
Spoken Language Outcomes After Early Cochlear Implantation in a Diverse, Multi-Institutional Cohort of Congenitally Deaf ChildrenEvan J Patel, Jihyun Stephans, Patricia Yoon, et al.
Cell Reports. Medicine|August 26, 2025
AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertionsAisha M Swaih, Sara Talbot, Adriana Savoca, et al.
Journal of Medicinal Chemistry|May 22, 2026
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical EvaluationJames M Smith, Bernard Barlaam, David Beattie, et al.
Cell Reports. Medicine|March 8, 2023
Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in miceRebecca Jarvis, Shu Fun Josephine Ng, Anna J Nathanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2023
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1Anna D Staniszewska, Domenic Pilger, Sonja J Gill, et al.
Journal of Medicinal Chemistry|September 28, 2024
Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion MutationsClare Thomson, Erin Braybrooke, Nicola Colclough, et al.
Journal of Medicinal Chemistry|September 27, 2021
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPsJeffrey W Johannes, Amber Balazs, Derek Barratt, et al.
Journal of Medicinal Chemistry|July 31, 2024
Discovery and <i>In Vivo</i> Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA CooperativityJames M Smith, Bernard Barlaam, David Beattie, et al.
Journal of Medicinal Chemistry|December 10, 2024
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective InhibitorJeffrey W Johannes, Amber Y S Balazs, Derek Barratt, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2022
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and TrapperGiuditta Illuzzi, Anna D Staniszewska, Sonja J Gill, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|July 8, 2026
Spoken Language Outcomes After Early Cochlear Implantation in a Diverse, Multi-Institutional Cohort of Congenitally Deaf ChildrenEvan J Patel, Jihyun Stephans, Patricia Yoon, et al.
Cell Reports. Medicine|August 26, 2025
AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertionsAisha M Swaih, Sara Talbot, Adriana Savoca, et al.
Journal of Medicinal Chemistry|May 22, 2026
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical EvaluationJames M Smith, Bernard Barlaam, David Beattie, et al.
Cell Reports. Medicine|March 8, 2023
Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in miceRebecca Jarvis, Shu Fun Josephine Ng, Anna J Nathanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2023
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1Anna D Staniszewska, Domenic Pilger, Sonja J Gill, et al.
Journal of Medicinal Chemistry|September 28, 2024
Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion MutationsClare Thomson, Erin Braybrooke, Nicola Colclough, et al.
Journal of Medicinal Chemistry|September 27, 2021
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPsJeffrey W Johannes, Amber Balazs, Derek Barratt, et al.
Journal of Medicinal Chemistry|July 31, 2024
Discovery and <i>In Vivo</i> Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA CooperativityJames M Smith, Bernard Barlaam, David Beattie, et al.
Journal of Medicinal Chemistry|December 10, 2024
Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective InhibitorJeffrey W Johannes, Amber Y S Balazs, Derek Barratt, et al.
Pageof 3